Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 2/20 | 0.55 |
| ▸ | SELP | P16109 | 2/20 | 0.55 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.54 |
| ▸ | SELE | P16581 | 4/20 | 0.52 |
| ▸ | MAG | P20916 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313946 | 0.96 | SIGLEC7 (0.57) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL29380203 | 0.96 | SIGLEC7 (0.57) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30654294 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30651776 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30652535 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30654029 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30650037 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30652699 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30653924 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG | |
| SCHEMBL30649253 | 0.96 | SELP (0.53) | SELLSELPSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | claimed |
| US-20260115307-A1 | ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-30 | — | — | US | claimed |
| EP-4727571-A2 | ACTIVATION OF T-CELLS WITH MUTANT G-CSFR | Interius Biotherapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724464-A1 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724112-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOLOGICAL DISORDERS | Interius Biotherapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4720312-A2 | GENE EDITING COMPOSITIONS OF POLYPEPTIDES AND NUCLEIC ACIDS, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260092256-A1 | PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY | BAYLOR COLLEGE OF MEDICINE (US) | 2026-04-02 | — | — | US | claimed |
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | ANGELES THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | ANGELES THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4689123-A1 | IL-2 VARIANTS WITH IMPROVED STABILITY AND COMPOSITIONS THEREOF | WuXi Biologics Ireland Limited (IE) | 2026-02-11 | — | — | EP | claimed |
| WO-2022076364-A1 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS | AOA DX (US) | 2022-04-14 | — | — | WO | claimed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | claimed |
| US-20220090132-A1 | CAR T CELL METHODS AND CONSTRUCTS | ABINTUS BIO INC (US) | 2022-03-24 | — | — | US | claimed |
| WO-2022052981-A1 | CHIMERIC ANTIGEN RECEPTOR COMPRISING NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF | 南京北恒生物科技有限公司 | 2022-03-17 | — | — | WO | claimed |
| WO-2022048523-A1 | CHIMERIC ANTIGEN RECEPTOR TARGETING NK ACTIVATED RECEPTOR | 南京北恒生物科技有限公司 | 2022-03-10 | — | — | WO | claimed |
| CN-114106192-A | Bispecific antibodies and uses thereof | 广州爱思迈生物医药科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2022033537-A1 | ENGINEERED IMMUNE CELL AND USE THEREOF | 南京北恒生物科技有限公司 | 2022-02-17 | — | — | WO | claimed |
| WO-2022022745-A1 | NOVEL CO-STIMULATORY DOMAIN AND USES THEREOF | 南京北恒生物科技有限公司 | 2022-02-03 | — | — | WO | claimed |
| WO-2022018262-A1 | T-CELLS EXPRESSING IMMUNE CELL ENGAGERS IN ALLOGENIC SETTINGS | CELLECTIS S.A. (FR) | 2022-01-27 | — | — | WO | claimed |
| EP-3941480-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | Score Pharma Inc. (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092256-A1 | PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY | IL4, IL2, PBK | SELL 224/4885SELP 164/4885SIGLEC7 170/4885 |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | NFRKB, NFATC1, NFKBIA | SELL 330/4885SELP 557/4885SIGLEC7 1202/4885 |
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | CD4, HLA-DRB1, SARS1 | SELL 480/4885SELP 279/4885SIGLEC7 345/4885 |
| US-20260115307-A1 | ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES | FUCA1, FUCA2, SIGLEC9 | SELL 80/4885SELP 661/4885SIGLEC7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.